<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03292744</url>
  </required_header>
  <id_info>
    <org_study_id>VitaminDIndonesia</org_study_id>
    <nct_id>NCT03292744</nct_id>
  </id_info>
  <brief_title>Effect of Alfacalcidol to Respiratory Infection and Immune Response of Indonesian Elderly</brief_title>
  <official_title>Effect of Alfacalcidol Supplementation to Respiratory Infection, Inflammatory Markers and CD4/CD8 Ratio of Indonesian Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D has been known to influence immune response through Vitamin D Receptor in Immune
      Cells, but only few has been known about the effect alfacalcidol, a vitamin D analog to
      immune system. In elderly, immune disregulation or immunosenecence have great impact to
      infection response. This study is aimed to determine the effect of alfacalcidol
      supplementation in vitro and in vivo to respiratory infection incidence and inflammatory
      markers, as well as T cell lymphocyte subset in Indonesian elderly patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consist of 2 designs. First is in vitro study to investigate the effect of
      alfacalcidol supplementation to IL-6, IL-10 and IFN gamma regulation in Peripheral Blood
      Mononuclear Cells (PBMC) of elderly and second design is randomised controlled trial to
      evaluate the effect of 3 months supplementation of alfacalcidol 0,5 mcg in respiratory
      infection, antibiotic use, inflammatory markers, CD4/CD8 ratio and CD8+ CD28+ in Indonesian
      elderly with various level of frailty syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2017</start_date>
  <completion_date type="Anticipated">December 15, 2017</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>upper respiratory tract infection incidence</measure>
    <time_frame>90 days</time_frame>
    <description>incidence of URTI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>lower respiratory tract infection incidence</measure>
    <time_frame>90 days</time_frame>
    <description>incidence of LRTI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>inflammatory markers</measure>
    <time_frame>day 90</time_frame>
    <description>IL6, IL10 and IFN gamma in PBMC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell subset</measure>
    <time_frame>day 90</time_frame>
    <description>CD4/CD8 ratio, CD8+ CD28- percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>antibiotic use</measure>
    <time_frame>90 days</time_frame>
    <description>any antibiotic prescribed by physician</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Frail Elderly Syndrome</condition>
  <condition>Elderly Infection</condition>
  <arm_group>
    <arm_group_label>Alfacalcidol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alfacalcidol 0,5 mcg once daily for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Amylum same capsule form, weight and colour with treatment arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfacalcidol</intervention_name>
    <description>alfacalcidol 0,5 mcg</description>
    <arm_group_label>Alfacalcidol</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>1 alpha hydroxy cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elderly age more than 60

          -  Willing to join research

        Exclusion Criteria:

          -  In acute infection

          -  Using NSAID or steroid

          -  Liver failure

          -  Hypercalcemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aulia Rizka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitas Indonesia / Cipto Mangunkusumo Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aulia Rizka, MD</last_name>
    <phone>+628125265600</phone>
    <email>dr.auliarizka@yahoo.co.id</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aulia Rizka, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cipto Mangunkusumo National Hospital</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aulia Rizka, MD</last_name>
      <phone>+628125265600</phone>
      <email>dr.auliarizka@yahoo.co.id</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Aulia Rizka</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>immunosenescence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Alfacalcidol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

